Can a new drug boost the power of chemoradiation against head and neck cancer?

NCT ID NCT06145412

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase II trial is testing whether adding the experimental drug xevinapant to the standard post-surgery chemoradiation treatment can improve outcomes for people with high-risk head and neck cancer. The study enrolls adults with certain types of head and neck cancer who have had surgery to remove their tumors. Participants receive xevinapant alongside cisplatin and radiation therapy, and the researchers will track how long they live without the cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: xevinapant combined with cisplatin and radiation therapy
What this could lead to: If successful, this could lead to a new treatment option that reduces the risk of cancer recurrence in high-risk head and neck cancer patients.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not be conclusive. The combination may also increase side effects compared to standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester

East White Plains, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.